Latest From Medigene AG
After receiving major backing for its strategy of targeting clonal neoantigens, Achilles's CEO tells Scrip that the UK firm's manufacturing prowess gives it an edge over competitors.
Management outlined four new oncology and one rare disease program during an analyst day. CEO Nick Leschly also talked to Scrip about staying focused on R&D as other gene therapy players get bought out.
Roivant has launched its 16th Vant, called Cytovant, which hopes to be Asia's premier cell therapy company. It has inked a deal worth potentially $1bn with Germany's Medigene to develop TCR immunotherapies and a dendritic cell vaccine.
Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Gene Therapy, Cell Therapy
- Large Molecule
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Medigene AG
- Senior Management
Dolores Schendel , PhD, CEO & CSO
Axel-Sven Malkomes , CFO & Chief Bus. Dev. Officer
Kai Pinkernell, MD, CMO & Chief Dev. Officer
- Contact Info
Phone: (49) 89 20 00 33 0
Lochhamer Str. 11
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.